Table 2. DNMT inhibitors.

Chemical Name	Mechanism of Action	Cancer Type	Clinical Stage
5-Azacytidine	Cytosine analog	High-risk myelodysplastic syndromes (MDS)	FDA approved for treatment of MDS [48]
5-Aza-2’-deoxycytidine	Cytosine analog	(MDS)	FDA approved for treatment of MDS [48]
SGI-110	Cytosine analog	Acute myelogenous leukemia (AML) and MDS	Phase III clinical trial in AML [53]
5-Fluro-2’-deoxycytidine	Cytosine analog	Refractory Solid Tumors	Phase II clinical trial in refractory solid tumors [161]
Zebularine	Cytosine analog	Human bladder cancer, AML cell lines and primary AML samples	Preclinical [161]
CP-4200	Cytosine analog	MDS	Preclinical [161]
RG108	Small molecule inhibitor	Endometrial cancer	Preclinical [161]
Nanaomycin A	Small molecule inhibitor	A549, HL60, and HCT116 cancer cell lines	Preclinical [161]
Procainamide	Antiarrythmic drug	Cloned T-cell lines	Preclinical [55]
Hydralazine	Antidiuretic	Cloned T-cell lines	Preclinical [55]
Valproic acid	Antiepileptic and mood stabilizer	AML or MDS	Preclinical [76]